Larazotide, also written larazotide acetate or AT-1001, is an eight amino acid peptide built to do one specific job: tighten the seals between the cells lining your intestine.
Those seals are called tight junctions, and they decide what gets through the gut wall into the bloodstream. When they loosen, larger fragments of food and bacteria can cross over and provoke an immune reaction. This is the mechanism behind the idea of a leaky gut, and larazotide is the most seriously studied drug ever aimed at it.
It came out of research on cholera. Scientists studying a cholera toxin that pries tight junctions open worked backwards to design a peptide that blocks the same pathway, acting against a human protein called zonulin that does something similar.
It is taken as an oral capsule before meals and is designed to stay in the gut rather than being absorbed. That makes it unusual among peptides: the point is for it to act locally and never reach the bloodstream.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
No reviews yet. Be the first.
Larazotide has an unusually complete research trail for a peptide, including a genuine Phase 3 program, and that is exactly why it is worth reading carefully.
The mid stage results were encouraging. In Phase 2 trials, people with celiac disease who took larazotide alongside a gluten challenge had less severe symptoms than those on placebo. A systematic review and meta-analysis of the randomized trials found it was safe and better than placebo for symptom relief.
Then the Phase 3 CeDLara trial failed to meet its primary endpoint in 2022. That result matters. It is the difference between a promising idea and a proven treatment, and it left both the regulatory path and the underlying zonulin theory in question.
There is separate work showing it helps repair tight junctions in injured intestinal tissue, including a study in ischemia-damaged pig intestine, which supports the mechanism even though the celiac trial did not deliver.
The takeaway is a useful one for anyone reading peptide claims generally. Larazotide had a plausible mechanism, real mid stage results, and serious funding behind it, and it still did not clear the final hurdle. Compounds sold with far less evidence should be read with that in mind.